Ameriprise
GLUE icon

Ameriprise’s Monte Rosa Therapeutics GLUE Stock Holding History

Ameriprise’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.28M Buy
383,335
+347,338
+965% +$6.56M ﹤0.01% 2107
2026
Q1 		$592K Sell
35,997
-86,167
-71% -$1.65M ﹤0.01% 3525
2025
Q4 		$1.92M Buy
+122,164
New +$1.65M ﹤0.01% 3026
2023
Q2 		– Sell
-10,955
Closed -$85.3K – 3940
2023
Q1 		$85.3K Sell
10,955
-1,754
-14% -$12.2K ﹤0.01% 3843
2022
Q4 		$97K Sell
12,709
-377
-3% -$3.14K ﹤0.01% 3811
2022
Q3 		$107K Buy
+13,086
New +$120K ﹤0.01% 3814

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's GLUE Position: Q2 2026 in Review

Ameriprise increased its Monte Rosa Therapeutics (GLUE) stake by 965% in Q2 2026, buying an estimated $6.56M and bringing the position to 383,335 shares worth $9.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2107.

Ameriprise first reported a position in GLUE in Q3 2022 and has held it in 6 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Ameriprise held 383,335 shares of Monte Rosa Therapeutics worth $9.28M as of Q2 2026.
  • Ameriprise bought 347,338 Monte Rosa Therapeutics shares in Q2 2026, an estimated $6.56M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2107 holding.
  • Ameriprise first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.